申慧丽

(河南省开封市第二人民医院，河南 开封 475002）

重组人干扰素 1 b雾化吸入治疗小儿反复呼吸道感染6 0例临床观察

申慧丽

(河南省开封市第二人民医院，河南 开封 475002）

目的分析重组人干扰素 1b雾化吸入治疗小儿反复呼吸道感染的临床价值。方法 选取医院2014年10月至2016年10月收治的反复呼吸道感染患儿120例，随机分为试验组和对照组，各60例。对照组患儿给予止咳、平喘、退热、抗感染等常规治疗，试验组患儿在此基础上加用重组人干扰素 1b雾化吸入治疗。结果 试验组总有效率为96．67%，明显高于对照组的85．00%（P＜0．05）；试验组治疗后的CD4+及CD4+／CD8+高于对照组，CD8+低于对照组，组间对比有显著性差异（P＜0．05）。结论 重组人干扰素 1b雾化吸入治疗小儿反复呼吸道感染，能尽早改善患儿的临床表现，提高免疫功能，值得临床推广。

小儿；反复呼吸道感染；重组人干扰素 1b；免疫功能；临床疗效

Abstract：Objective To analyze the clinical value of aerosol inhalation of recombinant human interferonα1b in the treatment of children with recurrent respiratory tract infection（RRTI）．M ethods Totally 120 children with RRTI treated in our hospital from October2014 to October 2016 were selected and random ly divided into the experimental group and the control group，60 cases in each group.The control group was given conventional treatment of relieving cough，relieving asthma，reducing fever and anti－infection，on this basis，the experimental group was additionally treated with aerosol inhalation of recombinant human interferonα1b.Results The total effective rate of the experimental group was 96.67%，which was significantly higher than 85.00% of the control group（P＜0.05）.After treatment，CD4+and CD4+／CD8+in the experimental group were significantly higher than those in the control group，while CD8+was significantly lower than that in the control group（P＜0.05）.Conclusion Aerosol inhalation of recombinant human interferonα1b in the treatment of children with RRTI can improve the clinical manifestation and the immune function of the children as soon as possible，it is worthy of clinical promotion.

Key words：children；recurrent respiratory tract infection；recombinant human interferonα1b；immune function；clinical effect

反复呼吸道感染（RRTI）是指儿童1年内上、下呼吸道感染次数超过10次的一种呼吸道疾病[1]，尤其在2～6岁儿童中患病率较高。研究表明，小儿RRTI在儿科疾病中约占20%[2]。该病发病机制较为复杂，临床认为主要与缺乏维生素、免疫功能低下、生活环境、喂养不当等因素相关。患儿临床症状包括打喷嚏、咽喉肿痛、鼻塞、发热等，全年均可发病，其中冬、春季患病率高，严重时可导致眼部、口腔、颈部淋巴结等部位出现不适症状，若病情进一步进展，则会诱发多种并发症，如肺炎、支气管炎等[3－4]。目前，临床大多予以止咳化痰、抗病毒等常规对症治疗，虽能暂时控制病情，但总体疗效不理想。……